<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancerToshiyuki Hirano, Kenzo Soejima, Hiroyuki Yasuda et al.|Oncotarget|2015Cited by 159
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung CancerMasayoshi Miyawaki, Kenzo Soejima, Tomoko Betsuyaku et al.|Molecular Cancer Research|2016Cited by 73
Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutationsHanako Hasegawa, Kenzo Soejima, Hiroyuki Yasuda et al.|Lung Cancer|2018Cited by 50
Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cellsKeiko Ohgino, Kenzo Soejima, Hideki Terai et al.|Cancer Science|2020Cited by 13
Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung CancerTetsuo Tani, Kenzo Soejima, Ichiro Nakachi et al.|Cancer Management and Research|2021Cited by 7